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Shiga toxin (Stx) binding to polymorphonuclear neutrophils (PMN) is hypothesized 
to play a role in the pathogenesis of Shiga toxin-producing Escherichia coli (STEC) disease 
in humans. Pigs are an excellent model for studying the role of PMN in STEC disease 
because, like humans, they are susceptible to Stx-mediated disease and Stx binds to porcine 
PMN in vitro. The objectives of this study were to develop a flow cytometric assay to 
monitor Stx2 binding under conditions required for functional studies (37°C in cell culture 
medium) and to evaluate the functional effects of Stx2 on porcine granulocytes. Binding and 
internalization of Stx2, or the non-toxic binding subunit of Stx2 (Stx2B), by isolated 
granulocytes, and the effects on apoptosis and oxidative burst were monitored by flow 
cytometry. Granulocyte preparations contained PMN and eosinophils (EOS) which bound 
and internalized Stx2 and Stx2B. Similar percentages of Stx2+ granulocytes were detected 
when Stx2 incubation was performed at 4°C and 37°C. Incubation with Stx2, but not with 
Stx2B, increased the mean percentage of apoptotic cells and reduced the mean percentage of 
cells capable of an oxidative burst. Pre-incubation of Stx2 with monoclonal antibodies 
against the Stx2B prevented Stx2 binding and effects on apoptosis and oxidative burst. The 
demonstration that Stx interacts with both porcine PMN and EOS in vitro extends the 
evidence that granulocytes, may contribute to STEC pathogenesis. The availability of a 
porcine Stx-mediated disease model will facilitate further investigations of the role of 
granulocytes in STEC disease. 
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CHAPTER 1: INTRODUCTION 
General Introduction 
Shiga toxin-producing E. coli (STEC) cause hemorrhagic colitis and hemolytic 
uremic syndrome (HUS) in humans worldwide. HUS is a life-threatening systemic 
complication of STEC infection and the leading cause of acute renal failure in children (98). 
Shiga toxins 1 and 2 (Stx 1 and 2) are important virulence factors thought to be the major 
mediators of STEC-induced HUS (6). These potent cytotoxins bind to globotriaosylceramide  
(Gb3/CD77) receptors on mammalian cells, but the precise sequence of events leading from 
intestinal colonization with STEC to the development of systemic complications is not 
known.  Numerous studies indicate the involvement of polymorphonuclear neutrophils 
(PMN) (9, 10, 29, 32, 48, 59, 60, 72, 77, 118, 119, 120). However, the specific role of these 
inflammatory cells in this process is not known.  An increased understanding of the role of 
PMN in the pathogenesis of Stx-mediated disease will facilitate development of intervention 
strategies. 
PMN may contribute to the development of systemic complications during STEC 
infection by allowing Stx to reach circulation and carrying the toxin to target organs 
including the kidney. Transmigration of human PMN into the intestinal lumen in response to 
Stx-induced inflammatory signals (124, 125) facilitates the movement of Stx into the 
bloodstream (60) and Stx bound to circulating PMN can be detected in blood from human 
patients with HUS (9, 117, 120).  Human PMN do not express the Stx receptor Gb3/CD77, 
but appear to bind Stx via a lower affinity receptor (48, 119). The ability of PMN to transfer 
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bound Stx to sensitive cells expressing Gb3 (119) as well as to other PMN (10) in vitro 
provides evidence that PMN may play a role in transporting Stx to the kidneys and CNS.  
Stx2 binds to isolated human PMN and delays the onset of apoptosis in these cells (10, 77).  
A delay in PMN apoptosis may prolong the functional lifespan of these cells and the amount 
of time they are in circulation. Stx also triggers the PMN oxidative burst that may result in 
tissue damage (72).  
 Pigs are useful models for studying the role of Stx in disease development. Weaned 
pigs are susceptible to a naturally-occurring and experimentally-induced disease known as 
edema disease caused by STEC strains that produce Stx2e (17, 61). Neonatal pigs develop 
Stx-mediated disease following inoculation with STEC strains that produce Stx1, Stx2 or 
Stx2e (19, 20, 38, 50, 95). Systemic effects of Stx in pigs are similar to those seen in humans 
and include CNS (24, 38, 127) and kidney (50, 95) lesions. Currently, the mechanism by 
which Stx reaches circulation and the target organs in these animals is unknown.  Stx binds 
to porcine peripheral PMN in vitro (136). However, the functional effects of this binding 
have not been identified. 
The overall objectives of this study were to develop a flow cytometric assay for 
evaluating Stx2 binding to isolated porcine granulocytes under conditions suitable for 
granulocyte functional studies and to investigate the effects of Stx2 on porcine granulocyte 
functions, namely apoptosis and oxidative burst.  
 
Objectives and Specific Aims 
Statement of the research problem 
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 The functional effects of Stx binding to porcine granulocytes in vitro have not been 
investigated.   
Objective 1  
 Develop a flow cytometric assay for evaluating Stx2 binding under conditions 
required for functional studies. 
Specific aims: 
1)  Establish a flow cytometric Stx binding assay for use at 4°C. 
 The previously described rapid flow cytometric assay for detecting Stx binding to 
isolated porcine granulocytes (135) was designed as a rapid procedure in which primary and 
secondary detection antibodies are combined in the same incubation step. Although the rapid 
staining procedure reduces handling of the cells and the time needed to complete the assay, 
there may be a possibility of cross-reactions or reduced staining when the detection reagents 
are combined compared to a sequential assay procedure in which separate incubation and 
wash steps are used for each reagent. 
 Hypothesis: The rapid and sequential Stx2 binding detection assays produce similar 
results. 
 
2)  Optimize the Stx binding assay for use under conditions required for functional studies 
using incubation of granulocytes and Stx2 at 37°C in cell culture media. 
Functional assays must be carried out at 37ºC in cell culture medium. An important 
step before examining the functional effects of Stx2 on porcine granulocytes is to ensure that 
Stx2 binds to granulocytes under the required conditions. The flow cytometric Stx binding 
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assay will be optimized for use at 37ºC by determining the effects of incubation time, 
temperature, and medium on Stx2 binding. 
Hypothesis: Stx2 binds to isolated porcine granulocytes under conditions needed for 
functional studies. 
 
3)  Use flow cytometry to evaluate internalization of Stx2 and rStxB2 by porcine 
granulocytes.  
The Stx2 holotoxin targets the 28S rRNA and is by cells before it can exert any toxic 
effects. Although the StxB2 binding subunit has no toxic activity, it can affect cells through 
signaling pathways beginning with receptor binding at the cell surface. Internalization studies 
may yield information on how any functional effects of Stx2 or rStxB2 are mediated. 
Hypothesis: Stx2 and rStxB2 are internalized by isolated porcine granulocytes. 
 
Objective 2 
 Determine the effects of Stx2 on porcine granulocyte function. 
Specific Aims:  
1) Determine the effect of Stx2 on apoptosis of isolated porcine granulocytes.  
 Stx delays apoptosis in human granulocytes possibly extending their functional life 
span and increasing the amount of time the cells are in circulation. Delayed apoptosis may 
allow the transport of Stx to target organs and result in an increase in granulocyte-mediated 
tissue damage. Since pigs develop kidney and CNS lesions comparable to those observed in 
humans, Stx may have similar effects on apoptosis in porcine and human granulocytes.  
Hypothesis: Stx2 delays apoptosis of isolated porcine granulocytes. 
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2) Determine the effect of Stx2 on porcine granulocyte oxidative burst.  
Stx increases the oxidative burst of human granulocytes and inhibits their ability to 
respond to subsequent stimulation with phorbol 12-myristate 13-acetate (PMA). Stx2 may 
have a similar effect on the oxidative burst of porcine granulocytes. 
Hypothesis: Stx2 decreases the percentage of PMA-stimulated porcine granulocytes 
capable of an oxidative burst. 
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CHAPTER 2: LITERATURE REVIEW 
Introduction 
Some Shiga toxin producing E. coli (STEC), including serotype O157:H7, cause 
hemorrhagic colitis and hemolytic uremic syndrome (HUS) in humans. HUS is a potentially 
fatal condition characterized by hemolytic anemia, thrombocytopenia, and acute renal failure. 
Of the estimated 70,000 cases of STEC infection in the United States each year (83), up to 
10% develop HUS. HUS most often occurs in young children and is the leading cause of 
acute renal failure in children in the United States (98). Healthy cattle are considered the 
primary reservoir for STEC (8) and undercooked meat, dairy, and vegetables contaminated 
with bovine feces are common sources of infection for humans (68). 
 
Shiga Toxins    
All STEC strains characteristically produce one or more potent cytotoxins called 
Shiga toxins (Stx) that are important virulence factors hypothesized to be responsible for the 
development of HUS (6). The two major types of Stx are Stx1 and Stx2 although several 
variants exist including Stx2c, Stx2d, Stx2e, Stx2f (63, 79, 84, 107). Stx1 and Stx2 are 
closely related to Shiga toxin produced by Shigella dysenteriae (89) and were initially named 
Verotoxins I and II or Shiga-like toxins I and II (12). Stx1 is 98% homologous to Shiga toxin 
produced by S. dysenteriae and differs by only one amino acid (114). In contrast, Stx2 shares 
only 56% sequence homology with Stx1 (66). Stx1 and Stx2 are antigenically distinct (112). 
Stx1 is neutralized by antiserum against Shiga toxin from S. dysenteriae, but Stx2 is not 
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neutralized by antiserum against Stx or Stx1 (112). The genes for Stx1 and Stx2 are encoded 
by bacteriophages (90) while the closely related Stx from S. dysenteriae is chromosomally 
encoded.   
Shiga toxins are AB toxins consisting of a 32kDa A (active) subunit non-covalently 
associated with five 7.7kDa B (binding) subunits (22). The A subunit is composed of two 
fragments, A1 and A2, joined by a disulphide bond (114) and proteolytic cleavage of the A 
subunit activates Stx (74). The A1 fragment is a 28S rRNA N-glycosidase necessary for the 
enzymatic activity of Stx (40) while the A2 fragment stabilizes the interaction between the A1 
and B subunits (3). The B subunits bind to specific receptors and studies with constructed 
hybrid toxins show that the receptor specificity of Stx is determined by the type of B subunit 
present (134). The A subunit of Stx2 but not Stx1 is accessible in the holotoxin and may also 
have a role in receptor specificity and binding (39).  
Stx1 and Stx2 have a similar mechanism of action, but there are some differences 
between the two. Infection with STEC strains expressing Stx2 is more often associated with 
severe disease (6) and Stx2 is more likely to lead to systemic complications in pigs (24). Stx1 
and Stx2 target different tissues and Stx2 has a lower LD50 in mice (101, 121). Stx1 and Stx2 
bind different sites on the Gb3 receptor (64). There are also differences in the intracellular 
transport of the toxins in some cell types (116).  
The membrane glycolipids called globotriaosylceramide (Gb3)  and 
globotetraosylceramide (Gb4) serve as the primary receptors for Stx on mammalian cells.  
Stx1 and Stx2 preferentially bind to Gb3 (75, 132) while Stx2e, a variant of Stx2 that causes 
edema disease in pigs, preferentially binds to Gb4 (21).  The fatty acid content (94) and length 
of the fatty acid chain (71) of the glycolipid receptors affect their specificity and affinity. 
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Both the presence of Gb3 on the cell membrane and the density of Gb3 in the lipid rafts are 
important factors in Stx binding (51). The differential organization of Gb3 in the lipid rafts 
may contribute to the age-associated susceptibility to HUS (70). Stx1 and Stx2 differentially 
bind to some Gb3 isoforms and do not bind to all Gb3 (14, 71, 76).  
There is evidence that Stx can bind to certain types of cells in a Gb3-independent 
manner. Stx appears to bind to a receptor with lower affinity than Gb3 (119) on human 
polymorphonuclear leukocytes (PMN) and to Gb3 as well as a second, unknown glycolipid 
receptor (15) on the surface of platelets. Stx modulates signaling pathways in a Gb3-negative 
human intestinal epithelial cell line (46, 108).  
Stx binds to glycolipid receptors via the B subunits and is subsequently endocytosed 
by many cell types (104). Stx binds uniformly over the cell surface at low temperatures but 
collects in clathrin-coated pits and is endocytosed when the temperature is increased (104). 
Although the preferential mechanism for Stx uptake involves clathrin-coated vesicles (106), a 
clathrin-independent mechanism has also been described for some cell types (88).  
Once the toxin is internalized it follows one of several paths through the cell. Cells 
that are not sensitive to Stx route the toxin to lysosomes for degradation (106). In cell types 
that are sensitive to Stx, the toxin is routed through the cells in a retrograde manner. Stx 
enters endosomal compartments before being routed to the trans-Golgi network, Golgi 
stacks, and the endoplasmic reticulum. The Stx B-subunit is routed through many cell types 
to the endoplasmic reticulum in the same manner as the holotoxin (67, 105). Retrograde 
transport of proteins usually requires a KDEL (Lys-Asp-Glu-Leu) sequence but the Stx B 
subunit does not contain one (65). Several experiments indicate that retrograde transport is 
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not controlled by Stx but by the composition and length of the fatty acid chain of the 
glycolipid receptors (103).   
Cleavage of the Stx A subunit into A1 and A2 subunits increases the activity of Stx 
(44, 74). Furin, a serine protease localized in the trans-Golgi network is the enzyme primarily 
responsible for this cleavage, but calpain or other enzymes in the cytosol may also be capable 
of cleaving the A subunit (43). Stx is transported to the cytosol by chaperone proteins in the 
endoplasmic reticulum (138) where it inhibits protein synthesis by affecting the 28S 
ribosomal RNA. Stx cleaves a N-glycosidic bond and releases an adenine base at the site of 
aminoacyl-tRNA docking, thereby inhibiting peptide chain elongation. This inhibition of 
protein synthesis quickly kills the cell (27).  
 
Hemolytic Uremic Syndrome 
In 5 to 10% of individuals infected with STEC, the disease will progress to hemolytic 
uremic syndrome (HUS), a condition characterized by hemolytic anemia, thrombocytopenia, 
and renal damage. HUS most often develops in pediatric and elderly patients and is the 
leading cause of acute renal failure in children in the U.S. (98, 100). Approximately 20% of 
HUS patients develop central nervous system (CNS) complications, including 
encephalopathy and stroke (91). The first symptoms of HUS usually appear 4-13 days after 





Shiga Toxin and Hemolytic Uremic Syndrome 
Stx plays a critical role in the pathogenesis of HUS. Histopathological analysis has 
revealed that Stx is cytotoxic to vascular and epithelial cells in the kidneys and to vascular 
cells in the central nervous system (CNS). Studies of Stx cytotoxicity in vitro  reveal that Stx 
can damage renal vascular endothelial (93), mesangial (110), tubular epithelial cells (18), and 
cerebral microvascular endothelial cells (28). Bacterial lipopolysaccharide (LPS) acts 
synergistically with Stx to increase cytotoxicity (78). The variable expression of Gb3 by 
different cell types may be responsible for the localization of damage to those areas 
expressing high numbers of the glycolipid receptors including the kidney and CNS (92, 122).   
Stx also contributes to the development of HUS through the Stx-mediated release of 
cytokines and chemokines that contribute to the inflammatory response (54). Stx upregulates 
the expression of tumor necrosis factor alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) 
by macrophages and monocytes (52, 53). TNF-alpha (25, 92, 111, 131) and IL-1 (128) 
increase Gb3 expression in endothelial cells and increase their sensitivity to the effects of Stx. 
Stx induces the release of TNF-alpha, IL-1, and other cytokines by renal tubule cells (57), 
glomerular epithelial cells (58), and cerebral microvascular endothelial cells (26), thus 
contributing to localized inflammation in the kidney and brain. Stx upregulates and stabilizes 
C-X-C chemokine mRNA, including IL-8, leading to an increase in production by intestinal 
epithelial cells in vitro (124, 125). This may increase the host inflammatory response and the 
influx of inflammatory cells into the intestine.   
Thrombocytopenia and hemolytic anemia are characteristics of HUS. Stx-mediated 
inhibition of protein synthesis and death of sensitive vascular endothelial cells leads to 
detachment of the cells from the basement membrane. Underlying prothrombotic proteins 
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such as collagen are exposed and can initiate platelet aggregation and fibrin deposition (129). 
Stx binding to platelets in vitro leads to aggregation and binding of platelets to endothelial 
cell membranes (69). The resulting formation of microthrombi in the vasculature inhibit 
blood flow, particularly in the kidney, leading to ischemic damage and renal failure (13). 
Hemolytic anemia occurs when red blood cells are damaged in circulation, possibly by 
passage through capillaries and small vessels that contain microthrombi formed as a result of 
vascular damage (96, 98).  
 
Shiga Toxins and PMN 
PMN appear to be involved in the pathogenesis of STEC-mediated disease. HUS 
patients have elevated PMN counts that are indicative of a poor prognosis (11, 102, 133). An 
increase in circulating PMN is a risk factor for developing HUS (4) and correlates with the 
severity of renal impairment in HUS patients (30, 31, 32). High numbers of PMN are also 
found in the glomeruli of children with HUS (62). IL-8, an activator of neutrophils, appears 
to be partly responsible as it is elevated in HUS patients and correlates with an increase in the 
percentage of peripheral PMN (35). Increased levels of elastase and evidence of degranulated 
PMN in the peripheral blood of patients with HUS indicate that the PMN are activated (30, 
32). PMN isolated from HUS patients readily adhere to and damage cultured endothelial cells 
(37, 86). Damage from activated, circulating PMN could increase endothelial cell injury and 
contribute to the development of the prothrombotic state in HUS. 
Studies with animal models of HUS provide further evidence that PMN have a role in 
the development of Stx-mediated disease. Mice intravenously injected with Stx2 develop an 
increased percentage of circulating neutrophils with enhanced cytotoxicity and adhesive 
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properties (2, 34). The increase in neutrophils also positively correlates with the degree of 
renal damage in mice (34). Similar experiments in mice depleted of granulocytes showed 
reduced Stx2-induced renal damage and lethality (33). Dutch belted rabbits administered 
intravenous Stx2 develop high levels of circulating PMN and PMN infiltration of the 
intestine and kidney (42). 
PMN may passively enable Stx transport from the intestinal tract to circulation.  
During STEC infections in humans, Stx upregulates the production of IL-8 and other 
chemotactic factors by intestinal epithelial cells, thus enhancing PMN infiltration (124, 125). 
PMN transmigration across polarized intestinal epithelial cells in vitro increases the 
movement of Stx across the cells in the opposite direction (60).  
Stx bind to PMN in vitro and Stx bound to circulating PMN can be detected in the 
blood of children with HUS (9, 10, 117, 118). Although human PMN bind Stx, they do not 
express Gb3 but are thought to express a different receptor with lower affinity (48, 119). 
PMN may be capable of transporting Stx to target organs. Human PMN pre-loaded with Stx 
transfer the toxin to human glomerular microvascular endothelial cells (GMVEC) resulting in 
inhibition of protein synthesis and cell death (119). PMN with bound Stx are also capable of 
transferring the toxin to Stx-negative PMN (10). Stx binds to other blood components 
including red blood cells (5), platelets (15), and monocytes (45, 97, 130) although these cells 
express Gb3/CD77 and there is no evidence they are involved in Stx transport.  
Several lines of evidence indicate that Stx has direct effects on PMN  function in vitro 
although studies have produced some conflicting data. Incubation of human PMN with Stx 
delayed spontaneous apoptosis, extending the functional lifespan of the cells (10, 77) while 
other studies reported no effect of Stx on PMN apoptosis (36, 72). Stx induced an oxidative 
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burst in human PMN but Stx treated PMN were less responsive when phorbol 12-myristate 
13-acetate (PMA) stimulation was used to elicit an oxidative burst (2, 72). Stx treatment also 
reduced the phagocytic ability of the PMN (72). Unlike human PMN, murine PMN express 
the Gb3 and Stx increases the percentage of apoptotic murine PMN (47, 48). Stx increases the 
release of reactive oxygen intermediates (ROI) and impairs phagocytosis in murine PMN as 
they do in human PMN (47). 
 
Shiga Toxin and Pigs 
Pigs are susceptible to both natural infections with STEC strains that cause edema 
disease and to experimental infections with STEC strains that cause disease in humans. 
Edema disease, primarily a disease of weaned pigs,  is caused by host-adapted STEC strains 
and is characterized by vascular necrosis, edema, and neurological complications (79). Stx2e, 
the Stx variant involved in edema disease, preferentially binds to Gb4 instead of Gb3 (21) and 
can be detected on circulating red blood cells in infected pigs (82). Edema disease has been 
used as a model to study the relationship between levels of Stx in the intestine and blood and 
the development of systemic complications (17). Pigs are a good model for studying the 
contribution of Stx to the development of disease because several features of Stx-mediated 
disease in pigs are similar to those in humans. Neonatal piglets inoculated intragastrically 
with STEC develop systemic complications (19, 20) and kidney lesions similar to those in 
humans with HUS (95). Gnotobiotic neonatal pigs develop brain lesions, vascular necrosis 
(38, 127), and thrombotic microangiopathy in the kidney (50). STEC producing Stx2 are 
more likely to lead to systemic disease in gnotobiotic pigs than strains that produce Stx1 or a 
combination of Stx1 and Stx2 (24). These results are similar to epidemiological data from 
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humans indicating that infection with STEC producing Stx2 is more likely to lead to severe 
disease and HUS. Pigs inoculated intravenously with Stx develop systemic disease including 
neurological signs and kidney lesions (41). Treatment of STEC-infected gnotobiotic piglets 
with antibody to Stx prevents the development of systemic disease (23, 87, 109). Stx1 and 
Stx2 bind to monocytes, alveolar macrophages, and to PMN in vitro (136).  
 
Conclusions 
PMN appear to be involved in the pathogenesis of Stx-mediated disease in humans, 
but their role is not well understood. Pigs are an excellent model for studying the role of 
PMN in STEC-mediated systemic disease. STEC-infected pigs develop STEC-mediated 
systemic disease characterized by kidney lesions and CNS complications similar to those 
seen in humans with HUS. Stx binds to PMN from pigs. The porcine model of Stx-mediated 
disease will facilitate further investigations of the interaction between Stx and PMN and 
identification of direct effects of Stx on PMN function and the role of PMN in the 
translocation of Stx out of the intestine, the transport of Stx to target organs, and the 
development of localized inflammation in target tissues.  
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CHAPTER 3: MATERIALS AND METHODS 
Stx2 and rStxB2 
 Purified Stx2 was generously provided by A. O’Brien, Uniformed Services University of 
the Health Sciences, Bethesda, Maryland. The recombinant StxB2 (rStxB2), consisting of the 
StxB2 (the non-toxic binding subunit of Stx2) carrying an affinity tag of 6 consecutive 
histidine residues (6xHis tag) at the amino terminus, was purified with the Ni-NTA Protein 
Purification Kit (Qiagen, Valencia, CA). Briefly, a 290-bp fragment encoding StxB2 (minus 
the start codon ATG) was PCR amplified from E. coli O157:H7 strain 86-24 (49) by using 
primers stx2B-F (5’GGTACCAAGAAGATGTTTATGGCGGTTTTA3’) and stx2B-R 
(5’GTCGACTCAGTCATTATTAAACTGCACTTCAG3’). The PCR amplified fragment 
was digested with BamH1 and Sal1 and cloned at the corresponding restriction sites of the 
expression vector pQE-80L. The recombinant plasmid stx2B-pQE80L was transformed into 
Escherichia coli M15. For rStxB2 expression, E. coli M15 containing stx2B-pQE80L was 
inoculated into Luria-Bertani broth supplemented with ampicillin (100 μg/ml) and incubated 
at 37°C with shaking (250 rpm). Once the culture reached an optical density (OD600) of 0.6, 
isopropyl-β-D-1-thiogalactopyranoside (IPTG; 1 mM) was added to induce transcription of 
stx2B leading to enhanced Stx2B expression. After 4 hours of growth in the presence of 
IPTG, the bacterial cells were collected by centrifugation (4000 x g, 20 minutes), 
resuspended in ice-cold phosphate buffered saline (PBS) and subjected to sonication (total of 
6 pulses with each pulse lasting 20 sec). The sonicated cells were centrifuged (10,000 x g, 30 
minutes, 4°C) to remove intact cells and cell debris. The supernatant was collected and 
applied to the Ni-NTA resin columns to bind the 6xHis tag on the rStxB2. The columns were 
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then washed and the protein eluted from the columns according to kit instructions. The total 
protein concentration of the preparation was estimated by using the Bio-Rad Protein Assay 
(Bio-Rad, Hercules, CA). The purity of the rStxB2 was assessed by SDS-PAGE and Western 
blot. 
 
Isolation of Porcine Granulocytes  
Blood samples were collected in heparin tubes (Becton Dickinson, Franklin Lakes, 
NJ) from eight healthy pigs (>6 months old) maintained at the National Animal Disease 
Center, Ames, IA, during the course of this study. Whole blood smears were prepared and 
stained with Wright’s stain (Sigma) for differential counts. Granulocytes were isolated under 
sterile conditions by density gradient centrifugation over Ficoll-Paque Plus (GE Life 
Sciences, Piscataway, NJ) as described elsewhere (Winter 2005) with minor modifications. 
Heparinized whole blood (15 ml) was mixed with an equal volume of 1X Hank’s balanced 
salt solution (HBSS). After centrifugation (400 x g, 30 minutes, 18°C), the plasma, buffy 
coat, and Ficoll layers were removed with a serological pipet and discarded. To minimize the 
number of contaminating lymphocytes and monocytes in the final preparation, the lower 
portion of the erythrocyte/granulocyte layer was removed with a clean pipette and transferred 
to a clean tube. Erythrocytes were removed from the granulocyte layer by hypotonic lysis 
with 27 ml of sterile dH2O followed by the addition of 3 ml 10X HBSS to restore isotonicity 
and centrifuged (600 x g, 20 minutes, 18°C). The lysis step was repeated, granulocytes were 
washed in 40 ml 1X HBSS, centrifuged (400 x g, 10 minutes, 18°C) and resuspended in 
either flow assay buffer (phosphate buffered saline containing 1% fetal calf serum [Hyclone, 
Logan, UT; heat inactivated], and 1% normal goat serum [Vector Laboratories, Burlingame, 
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CA]) or cell culture medium (RPMI 1640 [Invitrogen] containing 10% fetal calf serum, 3 μm 
beta-mercaptoethanol, penicillin and streptomycin [Sigma-Aldrich Corp., St. Louis, MO; 100 
IU/ml and 100 μg/ml, respectively]). Cell concentrations were determined using a 
hemacytometer. Viability was assessed by trypan blue (Sigma-Aldrich) exclusion and an 
initial viability of >90% was considered the minimum acceptable value. Smears prepared 
from the granulocyte preparations were stained with Wright’s stain (Sigma-Aldrich) for 
differential counts. 
 
Flow Cytometric Evaluation of Stx2 and rStxB2 Binding and Gb3/CD77 
Expression by Porcine Granulocytes  
Stx2 binding to porcine granulocytes at 4°C  
 In the previously-described rapid flow cytometric assay for detecting Stx binding to 
isolated porcine granulocytes (135), bound Stx is detected using an indirect 
immunofluorescence assay in which primary and secondary detection antibodies are 
combined in a single incubation step, rather than each reagent being added in separate 
incubations with additional wash steps. Although the rapid procedure reduces the handling of 
the granulocytes and the time needed to complete the assay, cross-reactions or reduced 
staining may occur when the detection reagents are combined. The rapid Stx binding assay 
uses constant shaking for the Stx2 incubation step. However, incubation of the granulocytes 
on a rotary shaker is not suitable for all of the planned studies. 
 To establish the 4°C Stx2 binding assay, pilot experiments were conducted to determine 
if Stx2 binding is affected by the additional time and handling from a sequential assay and if 
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shaking incubation is required for Stx2 binding. The Stx2 binding assays were modified and 
performed as described previously (Winter 2005). Two independent assays, each performed 
with granulocytes from 2 animals (4 animals total), were used to compare sequential and 
rapid Stx detection methods and to determine if Stx2 incubations can be performed without 
shaking. Isolated porcine granulocytes were diluted to a concentration of 4 x 106 cells/ml in 
flow assay buffer (described above). The diluted cells (50 l) were added to 96-well plates 
(Corning Costar, Lowell, MA) containing 100 μl of Stx2 (750 ng/ml, final well 
concentration) also diluted in flow assay buffer. Flow assay buffer was used for all 
subsequent dilutions and washes. All incubations and washes were performed at 4°C. The 
granulocytes were incubated with Stx2 for 1 hour, either with constant agitation on a 
microplate shaker (300 rpm) or statically, and then washed twice to remove unbound Stx2. 
For wash steps, the plates were centrifuged (400 x g, 3 minutes), the supernatant was 
decanted, and the granulocytes were resuspended in buffer (200 μl). The granulocytes were 
then sequentially incubated with rabbit anti-Stx2 antiserum (final dilution per well was 
1:1000, provided by A. O’Brien), washed, and incubated (30 minutes) with goat anti-rabbit 
IgG-fluorescein isothiocyanate (FITC) secondary antibodies (Southern Biotech, Birmingham, 
AL, final concentration per well was 4 μg/ml). For the rapid detection assay, the granulocytes 
were incubated for 30 minutes with primary and secondary antibodies in a single step. The 
granulocytes were washed twice and resuspended in 1X FACSLyse (Becton Dickinson) to 
fix the cells. All samples were tested in duplicate. Negative controls and secondary antibody 
controls were included in each assay. Granulocytes were incubated with flow assay buffer 
only for the negative controls and without the primary antibody (rabbit anti-Stx2 antiserum) 
for the secondary antibody controls. Granulocytes were analyzed within two hours by flow 
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cytometry and Stx2 binding was measured by the mean fluorescence intensity (MFI) and the 
percentage of positive granulocytes. Static Stx2 incubations and sequential incubations with 
primary and secondary Stx detection reagents were used in subsequent assays and hereafter 
referred to as the Stx2 binding assay. 
  
Flow cytometric analysis 
  A LSR II flow cytometer (Becton Dickinson) was used to acquire 10,000 events per 
sample. Granulocytes were initially analyzed for light scatter characteristics to determine size 
(forward scatter or FSC) and granularity (side scatter or SSC). Different cell populations 
within the isolated granulocytes were gated separately according to SSC signals. Secondary 
antibody and isotype controls were used to set analysis gates so that <2% of the cells in the 
control samples were positive. All flow cytometry data was analyzed with FlowJo software 
(Tree Star, Inc., Ashland OR).  
 
Fluorescence microscopic evaluation of Stx2 binding 
 In some assays, Stx2 binding to isolated porcine granulocytes at 4°C was also evaluated 
using fluorescence microscopy. Granulocytes (1-2 μl) from two independent flow cytometric 
Stx2 binding assays (2 assays, 2 animals/assay) were spotted onto slides (Probe-on-Plus, 
Fisher Scientific, Waltham, MA) before or after the FACSlyse (Becton Dickinson) fixation 
step. The slides were air-dried in the dark and cover slips were mounted with mounting 
medium (ProLong Gold, Invitrogen, Carlsbad, CA) containing DAPI (4'-6-diamidino-2-
phenylindole) to label nucleic acids. Slides were examined using an Eclipse E800 
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microscope (Nikon Instruments, Inc., Melville, NY). Digital images were taken with a 
Digital SPOT RT Slider camera (Diagnostic Instruments, Inc., Sterling Heights, MI) using 
MetaVue software (Universal Imaging Corp., Downingtown, PA). 
 
Flow cytometric rStxB2 binding assays  
 The binding subunit of Stx2 (Stx2B) has functional affects, which are mediated through 
signaling pathways initiated at the cell surface, on some cell types. Recombinant Stx2b 
(rStxB2) was included in this study to differentiate between effects mediated through the 
toxic action of the Stx2 A-subunit and those mediated by signaling pathways triggered by 
receptor binding. 
 The flow cytometric rStxB2 binding assays were performed as described for Stx2 
binding. Pilot experiments with 8.7-9000 ng/ml (final well concentration) of rStxB2 and 
checkerboard antibody titrations were performed to determine the optimal rStxB2 
concentration and saturating antibody concentrations for binding assays. The rStxB2 
concentration that resulted in the highest MFI value (6000 ng/ml, final well concentration) 
and the antibody concentrations that resulted in the highest signal to noise ratio (rabbit anti-
Stx2 antiserum at 1:100, goat anti-rabbit IgG-FITC at 4 μg/ml) were used in subsequent 
rStxB2 binding assays.  
 Binding of rStxB2 to isolated porcine granulocytes was evaluated in four independent 
assays with granulocytes isolated from four total animals (two animals per assay, each animal 
analyzed twice). The rStx2B binding assay was performed as described above for Stx2. 
Granulocytes were fixed with 1X FACSlyse and analyzed by flow cytometry within 2 hours. 
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Flow cytometric Gb3/CD77 receptor assay  
 Expression of the Stx2 receptor Gb3 ,also known as CD77, was assessed in four 
independent assays with granulocytes isolated from four total animals (each animal analyzed 
twice). The Gb3/CD77 flow cytometry assay was performed as described (137) with some 
modifications. Isolated porcine granulocytes (2 x 105 cells/well) were incubated with rat anti-
human CD77 clone 38.13 (20% vol/vol, AbD Serotec, Raleigh, NC), suitable for detection of  
Gb3/CD77 in non-human species, and mouse anti-CD172a (10 μg/ml, VMRD Inc., Pullman, 
WA), included as a granulocyte marker, for 30 minutes on ice. The granulocytes were 
centrifuged (400 x g, 3 minutes, 4°C), washed twice in flow assay buffer (200 μl) as 
described above, and incubated in goat anti-rat IgM-FITC (Southern Biotech, 6 μg/ml) and 
goat anti-mouse IgG1-phycoerytherin (PE) (Southern Biotech, 2 μg/ml) on ice for 30 
minutes. After two additional wash steps the cells were fixed in 1X FACSLyse and analyzed 
by flow cytometry within two hours. Negative controls including secondary antibody and 
isotype controls were included in the assay.  
 
Stx2 and rStxB2 binding to porcine granulocytes under conditions required for 
functional studies  
 For functional assays, porcine granulocytes must be incubated with Stx2 or rStxB2 in cell 
culture medium at 37°C. The 4°C Stx2 and rStxB2 binding assays were modified to optimize 
detection of Stx2 and rStxB2 binding to porcine granulocytes under these conditions. Effects 
of medium, temperature, and incubation time on Stx2 and rStxB2 binding were evaluated 
using granulocytes isolated from four animals (tested in four independent assays; two 
 22
animals per assay, 2 assays per animal. Granulocytes and Stx2 or rStxB2, diluted in flow 
assay buffer or cell culture medium (described above), were added to two duplicate sets of 
96-well plates (4 plates/set). One set was incubated at 4°C and the second set was incubated 
at 37°C for 15, 30, 60, or 120 minutes. All Stx2 and rStxB2 incubations were started at the 
same time; washes and Stx detection steps were staggered accordingly, and performed as 
described above. Stx2 and rStxB2 binding were measured by the mean fluorescence intensity 
(MFI) and percentage of positive granulocytes. 
 
Internalization of Stx2 and rStxB2  
Four independent internalization assays were performed with granulocytes isolated 
from four animals (2 animals/assay, 2 assays/animal) to determine if Stx2 and rStxB2 are 
internalized.  Porcine granulocytes were incubated with Stx2 (750 ng/ml) or rStxB2 (6000 
ng/ml) in cell culture medium for 30 minutes at 4°C as described above for the binding 
assays. The cells were washed once, resuspended in cell culture medium only, and incubated 
for an additional 30 minutes at either 37°C to allow uptake of the bound proteins or at 4°C as 
a control. The cells were returned to or maintained at 4°C and Stx2 or rStxB2 binding was 
detected by flow cytometry as described.  
A second type of assay was used to confirm that Stx2 and rStxB2 were internalized 
by porcine granulocytes. In four independent assays, granulocytes isolated from four animals 
(2 animals/assay, 2 assays/animal were incubated with Stx2 or rStxB2 in cell culture medium 
for 30 minutes at 4°C, washed once, resuspended in cell culture medium, and incubated for 
an additional 30 minutes at either 37°C or at 4°C as described above. Granulocytes were then 
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fixed with 1% paraformaldehyde (10 minutes, room temperature) and permeabilized with 1% 
saponin (5 minutes, room temperature) to allow detection antibodies to reach internalized 
Stx2 and rStxB2 as well as that on the surface. The granulocytes were incubated with 
detection antibodies diluted in permeabilization buffer (PBS, 1% fetal calf serum, 1% normal 
goat serum, 1% saponin), washed in permeabilization buffer, resuspended in 1X FACSLyse 
and analyzed by flow cytometry within one hour as described above. 
 
Effect of Stx2 on Granulocyte Apoptosis 
 Two independent assays using granulocytes from two animals (each animal analyzed 
once) were performed to examine the effect of Stx2 concentration and incubation time on 
apoptosis. Porcine granulocytes were isolated as described above, dispensed into sterile 96-
well plates, and incubated with cell culture medium alone (medium control) or with cell 
culture medium containing Stx2 (0.1-100 ng/ml) for 0.5, 2, 4, 6, and 18 hours of incubation 
at 37°C and 5% CO2. Plates were removed from the incubator at the appropriate times, 
centrifuged (400 x g, 3 minutes, room temperature) and the granulocytes were resupended in 
100μl annexin V binding buffer (Annexin V-FITC Apoptosis Detection Kit, Becton 
Dickinson). Annexin V-FITC (3 μl/well, Becton Dickinson) and propidium iodide (PI, 
5l/well, Becton Dickinson) were added to the cells and incubated for 15 minutes in the dark 
at room temperature. Granulocytes were analyzed within 1 hour by flow cytometry as 
described above. Viable cells were defined as annexin V negative and PI negative, early 
apoptotic cells were defined as annexin V positive and PI negative, and late apoptotic and 
dead cells were defined as annexin V positive and PI positive. 
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 The effects of Stx2 and rStxB2 on porcine granulocyte apoptosis were evaluated in four 
independent assays using granulocytes from four animals (each animal analyzed twice). For 
these assays, granulocytes were incubated with Stx2 (1 ng/ml) or rStxB2 (1 ng/ml). To 
determine Stx-specificity of the observed effects, granulocytes were incubated with Stx2 or 
rStxB2 combined with anti-StxB2 (1:500, Mab BC5 BB12, provided by N. Strockbine, 
Centers for Disease Control and Prevention, Atlanta, Georgia) to inhibit binding. Stx2 and 
rStxB2 were pre-incubated with anti-StxB2 at 4°C for 2 hours before incubation with 
granulocytes. Granulocytes were incubated with lipopolysaccharide (LPS) from E. coli 
O111:B4 (1 ng/ml, Sigma) as a control for any LPS present in the Stx2 or rStxB2 
preparations. Plates were incubated for 6 hours at 37°C and 5% CO2, then removed from the 
incubator and centrifuged (400 x g, 3 minutes, room temperature). Granulocytes were 
incubated with apoptosis detection reagents and analyzed by flow cytometry as described 
above.  
Effect of Stx2 on Granulocyte Oxidative Burst 
 The effects of Stx2 on porcine granulocyte oxidative burst were evaluated in four 
independent assays with granulocytes isolated from four total animals (two analyzed per 
assay, each animal analyzed twice). Granulocytes were incubated with medium, Stx2, 
rStxB2, Stx2 + Mab BC5 BB12, rStxB2 + Mab BC5 BB12, or LPS as described above for 
apoptosis assays. Plates were incubated for 6 hours at 37°C and 5% CO2. The plates were 
removed from the incubator after six hours and were centrifuged (400 x g, 3 minutes, room 
temperature). Granulocytes were resuspended in 100 μl dihydrorhodamine 123 (2.5 μM, 
Sigma-Aldrich) and incubated at 37°C for 10 minutes. Phorbol 12-myristate 13-acetate 
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(PMA, 100 μl, 12.5 μg/ml, Sigma-Aldrich) was added to the cells to induce an oxidative 
burst followed by incubation for an additional 10 minutes at 37°C. The cells were washed 
once in ice-cold wash buffer, kept on ice and analyzed by flow cytometry within one hour.  
 
Statistical Analysis 
 A Pearson correlation was calculated between the percentage of high SSC 
granulocytes determined by flow cytometry and the percentage of EOS determined by 
differential counts using SAS software (SAS Inc., Cary, NC). Repeated measures were 
collected for internalization and functional studies and data were statistically analyzed with 
SAS software using a General Linear Mixed Model (GLMM), a modified form of multiple 
regression. The independent variables of “treatment” and “day of assay” were analyzed as 
fixed effects and the independent variable “pig” was analyzed as a random effect. In order to 
determine if there were significant differences between specific treatments, t-tests were 
conducted as part of the GLMM. Significant results were designated as: P < 0.001 (***), P < 
0.01 (**), P < 0.05 (*). Differences with P > 0.05 were not considered significant. 
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CHAPTER 4: RESULTS 
Characterization of Granulocyte Preparations 
Microscopic examination of Wright's stained smears of the granulocyte preparations 
showed that these preparations contained two cell types, EOS and PMN. Flow cytometric 
light scatter analysis of the granulocyte preparations differentiated two cell populations: one 
with a high SSC signal (2-27% of total granulocytes) and a second with a low SSC signal 
(73-98% of total granulocytes) (Figure 1). The percentages of high SSC and low SSC cells 
determined by flow cytometry correlated with the differential cell count percentages of EOS 
(0-27%) and PMN (73-100%), respectively, (r = 0.61, P <0.01).  
  
Stx2 Binding to Porcine Granulocytes at 4°C 
 Pilot studies were performed to determine if the primary and secondary antibodies 
used to detect bound Stx2 could be added sequentially, rather than combined as in the 
previously described flow cytometric Stx binding assay (137). The percentages of Stx2-
positive high and low SSC granulocytes (>98% and >99%, respecitvely) and the mean 
fluorescence intensity (MFI) for high and low SSC granulocytes were similar with the two 
Stx2 detection methods (Figure 2). No differences in cell morphology or granularity profiles 
were detected by flow cytometric analyses.  Sequential incubations with primary and 
secondary detection antibodies are standard practice for flow cytometry assays and were used 
for all subsequent assays.  
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The percentages and MFI of Stx2 positive granulocytes were similar after 
granulocytes were incubated with Stx2 for 1 hour at 4°C on a rotary shaker or statically 
(Figure 11, Appendix). We interpreted these results as evidence that isolated granulocytes do 
not need to be agitated in order to achieve Stx2 binding and static incubations were used in 
all subsequent assays. 
 
Stx2 and rStxB2 Binding and Gb3/CD77 Expression at 4°C 
Flow cytometric analyses showed that both Stx2 and rStx2B bound to high SSC 
(>98%) and low SSC (>99%) granulocytes at 4°C, and that high SSC (>94%) and low SSC 
(>99%) granulocytes both expressed the Stx receptor Gb3/CD77 (Figure 3). 
Fluorescence microscopic analysis of the isolated granulocytes incubated with Stx2 at 4°C 
clearly showed that both PMN and EOS bound Stx2 (Figure 4). The EOS were identified by 
their characteristic increased red autofluorescence when examined using a TRITC filter. No 
FITC (green) fluorescence was detected on control slides spotted with cells incubated with 
flow assay buffer instead of Stx2. 
 
Stx2 Binding Under Conditions Required for Functional Studies 
Similar percentages of Stx2 positive granulocytes (>98%) were detected in samples 
incubated with Stx2 at 4°C or 37°C for 15 to 60 minutes, but the percentages (>72%) of 
Stx2-positive granulocytes were reduced in samples incubated with Stx2 at 37°C for 120 
minutes. There were no differences in the percentages of Stx2-positive granulocytes in 
samples incubated with Stx2 in flow assay buffer or cell culture medium. 
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The MFI of the high SSC granulocytes were similar for all samples incubated for 15 
to 120 minutes at 4°C (Figure 5A). In contrast, the MFI of the low SSC granulocytes were 
similar in samples incubated with Stx2 for 15 to 60 minutes at 4°C, but increased in samples 
incubated 120 minutes (Figure 5C). The MFI of both the high and low SSC populations 
decreased over time at 37°C (Figure 5B and D). The MFI of low SSC granulocytes was 
similar for all granulocytes incubated up to 30 minutes at either 4°C or 37°C (Figure 5C and 
D). In contrast, the MFI of high SSC granulocytes was consistently higher for granulocytes 
incubated with Stx2 at 4°C (Figure 5A) than for those incubated at 37°C (Figure 5B). 
 
 
rStxB2 Binding Under Conditions Required for Functional Studies 
Overall, similar percentages of rStxB2 positive granulocytes (>97%) were detected in 
samples incubated with rStxB2 at 4°C or 37°C for 15 to 30 minutes, but the percentages of 
rStxB2-positive granulocytes (>65%) were reduced in samples incubated with rStxB2 at 
37°C for 60-120 minutes. There were no differences in the percentages of rStxB2-positive 
granulocytes in samples incubated with rStxB2 in flow assay buffer or cell culture medium. 
The MFI of the low and high SSC granulocytes increased from 15 to 120 minutes at 
4°C with the exception of the high SSC granulocytes from pig 1 (Figure 6A and C). The MFI 
of both high and low SSC granulocytes at 37°C were reduced in comparison to high and low 
SSC granulocytes at 4°C (Figure 6). The MFI of the low SSC granulocytes decreased over 
time at 37°C (Figure 6D) while the MFI of the high SSC granulocytes were similar from 15-
120 minutes at 37°C (Figure 6B).  
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Internalization of Stx2 and rStxB2  
The reduction of Stx2 binding at 37°C described above provided presumptive 
evidence that Stx was internalized at 37°C. Flow cytrometry was used to compare Stx2 and 
rStxB2 binding on the cell surface after granulocytes were loaded with Stx2 at 4°C and then 
differentially incubated for an additional 30 minutes at 4°C or 37°C. Granulocytes were then 
incubated with detection reagents at 4°C. The MFI of granulocytes incubated at 4°C or 37°C 
were significantly different (P < 0.001) (Figure 7A and B).  
To confirm that Stx was internalized at 37°C, similar experiments were designed to 
detect both internalized and surface-bound Stx2 or rStxB2. In these experiments, 
granulocytes were fixed and permeabilized before incubation with detection reagents. As 
shown in Figure 7C, the differences between the MFI of the fixed and permeabilized 
granulocytes incubated at 4°C or 37°C were not as pronounced as the differences observed 
when surface-bound Stx or rStx2B were detected (7A and B).  However, these differences 
were still significant (P < 0.01). In this experiment, separate populations of high SSC and 
low SSC cells could not be detected by flow cytometry and were analyzed as one population. 
All of the cells had SSC cells signals comparable to those of low SSC cells, possibly due to 
degranulation of the high SSC cells when they were permeabilized. 
 
Effect of Stx2 on Apoptosis in Porcine Granulocytes 
Isolated porcine granulocytes were incubated for 0.5-18 hours with medium or Stx2 
(0.1-100 ng/ml). When cells were incubated with medium, the percentage of early apoptotic 
cells in the high SSC population increased from <3% initially to >40% after 6 hours. After 18 
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hours, the percentage of early apoptotic high SSC granulocytes was >30% indicating that 
some of the early apoptotic cells had transitioned into late apoptotic or dead cells. The 
percentage of early apoptotic low SSC granulocytes in the medium control increased from 
<2% initially to >75% at 18 hours. Incubation with Stx2, at all tested concentrations, 
increased the percentage of early apoptotic cells compared to a medium only control after 2, 
4, and 6 hours of incubation (Figure 8). The largest difference between granulocytes 
incubated with Stx2 or with medium was observed after 6 hours. Fewer than 2% of 
granulocytes were late apoptotic or dead after 0.5-6 hours of incubation with Stx2 (not 
shown). By 18 hours of incubation, the percentage of early apoptotic granulocytes decreased 
as the percentage of late apoptotic or dead granulocytes increased (not shown). Similar 
results were obtained for both high SSC (Fig. 8A) and low SSC (Fig. 8B) granulocytes. 
Incubation of isolated granulocytes with Stx2 (1 ng/ml) for 6 hours significantly 
increased the mean percentage of apoptotic cells compared to a medium control for the high 
SSC (P < 0.001) and low SSC populations (P < 0.001) (Figure 9A and B). The effects of Stx2 
on apoptosis were inhibited when Stx2 was pre-incubated with antibodies against the StxB2 
to inhibit toxin binding. Incubation of granulocytes with rStxB2 (1 ng/ml), the non-toxic 
binding subunit, did not effect apoptosis in either cell population (Figure 9A and B). 
Incubation with LPS (1 ng/ml) had the opposite effect of Stx2 and significantly decreased the 
mean percentage of apoptotic PMN (P < 0.001) (Figure 9B). 
 
Effect of Stx2 on the Oxidative Burst of Porcine Granulocytes 
Incubation with Stx2 (1 ng/ml) for 6 hours significantly decreased the mean 
percentage of high SSC (P < 0.001) and low SSC (P < 0.001) granulocytes capable of an 
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oxidative burst induced by PMA (Figure 10A and B). The effects of Stx2 were inhibited by 
pre-incubation of Stx2 with antibodies against the StxB2 to inhibit toxin binding. Incubation 
with rStxB2 (1 ng/ml) had no effect on the oxidative burst in either high SSC or low SSC 
cells (Figure 10A and B).  LPS (1 ng/ml) had the opposite effect of Stx2 and increased the 
induced oxidative burst in the high SSC (P < 0.05) and low SSC (P < 0.01) cells (Figure 10). 
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Figure 1. Flow cytometric side scatter (SSC) vs. forward scatter (FSC) plot of isolated 
porcine granulocytes showing porcine granulocyte preparations contained two cell 
populations distinguished by high (A) and low (B) SSC signals. Granulocytes isolated from 







Figure 2. Stx2 binding to isolated porcine granulocytes and detected by the rapid or 
sequential assay. Stx2 binding was detected using the rapid assay where detection reagents 
were combined in one incubation step (white histogram) or the sequential assay where 
detection reagents were incubated with the granulocytes in two separate steps (shaded 
histogram). Stx2 positive granulocytes with similar MFI were identified by flow cytometry 
with both detection methods. Stx2 bound similarly to high and low SSC granulocytes. Flow 







Figure 3. Stx2 and rStxB2 binding and Gb3/CD77 expression by isolated porcine 
granulocytes at 4°C. To detect Stx2 or rStxB2 binding, isolated granulocytes were incubated 
with Stx2 or rStxB2 for 1 hour, at 4°C, washed, incubated with primary and secondary 
detection antibodies in two separate steps, washed, fixed and analyzed by flow cytometry. To 
detect Gb3/CD77 expression, isolated granulocytes were incubated with anti-CD77 primary 
antibody for 30 minutes at 4°C, washed, incubated with secondary detection antibody, 
washed, fixed and analyzed by flow cytometry. Flow cytometry histograms show Stx2, 
rStxB2 or Gb3/CD77 detection (shaded histograms) and corresponding controls incubated 
without Stx2, rStxB2, or anti-CD77 (white histograms) for high SSC (A) and low SSC (B) 
granulocytes. Histograms are representative of results obtained for each animal (n = 4) from 





Figure 4. Fluorescence microscopic analysis of Stx2 binding to isolated porcine 
granulocytes. Granulocytes were incubated with Stx2 at 4°C for 30 minutes, washed, 
incubated with Stx2 detection reagents and spotted onto slides for evaluation. Bound Stx2 
was identified by green fluorescence. EOS (indicated with arrows) were differentiated from 
PMN by their characteristic intense red autofluorescence when examined with a tetramethyl 
rhodamine isothiocyanate (TRITC) filter. DAPI was included for visualization of nucleic 






Figure 5. Stx2 binding to high SSC (A and B) and low SSC (C and D) granulocytes at 4°C 
(A and C) and 37°C (B and D). Isolated porcine granulocytes were incubated with Stx2 at 
4°C (A and C) or 37°C (B and D) in cell culture media for 15-120 minutes before incubation 
with Stx2 detection reagents, fixation, and analysis. Graphs show MFI data for each animal 
(n = 4) from four independent experiments (each animal sampled twice and tested on 





Figure 6. rStxB2 binding to high SSC (A and B) and low SSC (C and D) granulocytes at 4°C 
(A and C) and 37°C (B and D). Inset graphs show the MFI data for high and low SSC 
granulocytes at 37°C with a decreased y-axis scale. Isolated porcine granulocytes were 
incubated with rStxB2 at 4°C (A and C) or 37°C (B and D) in cell culture media for 15-120 
minutes before incubation with rStxB2 detection reagents, fixation, and analysis. Graphs 
show MFI data for each animal (n = 4) from four independent experiments (each animal 





Figure 7. Internalization of Stx2 and rStxB2 by isolated porcine granulocytes. Granulocytes 
were loaded with Stx2 or rStxB2 at 4°C for 30 minutes, washed, and either maintained at 4°C 
for an additional 30 minutes (shaded histograms) or transferred to 37°C for 30 minutes 
(white histograms). All granulocytes were kept at 4°C for subsequent incubations with 
detection reagents. To identify surface bound Stx2 or rStxB2 (A and B), granulocytes were 
then incubated with detection reagents, fixed and analyzed by flow cytometry. To identify 
both surface and internalized Stx2 or rStxB2 (C), granulocytes were fixed and permeabilized 
before the incubation with detection reagents. Flow cytometry histograms show Stx2 or 
rStxB2 on the surface of high SSC (A) and low SSC (B) populations of granulocytes. It was 
not possible to detect separate high and low SSC populations of permeabilized granulocytes 
(C) because permeabilization caused degranulation of the cells. Histograms are 
representative of results obtained for each animal (n = 4) from four independent experiments 





Figure 8. The effects of Stx2 concentration and incubation time on granulocyte apoptosis. 
Isolated porcine granulocytes were incubated with medium or Stx2 (0.1 – 100 ng/ml) for 0.5 
– 18 hours at 37°C. The granulocytes were incubated with Annexin V-FITC and propidium 
iodide (PI) and early apoptotic cells were defined as Annexin V positive and PI negative. The 
percentage of early apoptotic cells was determined by flow cytometry analysis. The data are 
representative of results obtained from two independent experiments with each animal (n=4) 








Figure 9. Effect of Stx2 on early apoptosis of isolated porcine granulocytes. Granulocytes 
were incubated at 37°C for 6 hours with Stx2 (1 ng/ml) or rStxB2 (1 ng/ml). To show Stx2-
specific effects, some samples were incubated with Stx2 or rStxB2 pre-incubated for 2 hours 
with anti-StxB2 to inhibit binding. Granulocytes were incubated with medium as a negative 
control or LPS as a control for any LPS in the Stx2 or rStxB2 preparations. The percentage of 
early apoptotic cells was determined by flow cytometry as described in Fig. 8. Duplicate 
values for each animal (n = 4) from four independent experiments (each animal sampled 
twice and tested on separate days) are shown for high SSC (A) and low SSC (B) 





Figure 10. Effect of Stx2 on the oxidative burst of isolated porcine granulocytes. 
Granulocytes were incubated at 37°C for 6 hours with Stx2 (1 ng/ml) or rStxB2 (1 ng/ml). To 
show Stx2-specific effects, granulocytes were incubated with Stx2 or rStxB2 pre-incubated 
for 2 hours with anti-StxB2 to inhibit binding. Granulocytes were incubated with medium as 
a negative control or LPS as a control for any LPS in the Stx2 or rStxB2 preparations. The 
percentage of oxidative burst positive cells was determined by flow cytometry. Duplicate 
values for each animal (n = 4) from four independent experiments (each animal sampled 
twice and tested on separate days) are shown for high SSC (A) and low SSC (B) 
granulocytes. P values were determined by multiple regression analysis. P < 0.001 (***), P < 





CHAPTER 5: DISCUSSION 
 
The results of this study confirmed that Stx2 binds to isolated porcine granulocytes 
and provided evidence that Stx2 is internalized by and directly affects the function of porcine 
granulocytes in vitro. These results extend the evidence that PMN play a role in the 
pathogenesis of Stx-mediated disease. Stx2 also bound to isolated porcine EOS and altered 
apoptosis and oxidative burst. To the best of our knowledge, this is the first report of Stx2 
binding and functional effects on EOS of any species. 
Flow cytometric analysis of the porcine granulocyte preparations used in the current 
study revealed the presence of two cell populations that differed in granularity. The side 
scatter signals of the high SSC and low SSC populations were consistent with those 
described for EOS (126) and PMN (80), respectively. The identity of the cells could not be 
absolutely determined by flow cytometry because specific antibodies for identifying porcine 
EOS were not available at the time of this study. EOS and PMN were the only cell types 
noted in the analysis of Wright's stained smears of the granulocyte preparations. The 
percentages of high SSC and low SSC cells determined by flow cytometry correlated 
significantly with the percentages of EOS and PMN, respectively, determined by differential 
counts. Based on this data, we interpreted the high SSC population to be EOS and the low 
SSC population to be PMN. 
The high SSC population of granulocytes, interpreted to be EOS, bound Stx2 and 
expressed Gb3/CD77. Stx2 binding and Gb3/CD77 expression by porcine EOS were not 
observed in previous flow cytometric studies of Stx2 binding to porcine granulocytes (135). 
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Scatter analysis of the granulocyte preparations in that study revealed a single cell population 
although it was noted that the presence of EOS in the granulocyte gate could not be ruled out 
because reagents to identify porcine EOS were not available (135). 
Analysis of Stx2 binding by fluorescence microscopy showed that Stx2 bound to cells 
with high red autofluorescence when examined under TRITC filters, interpreted to be EOS, 
and to cells without this autofluroescense (PMN). Stx2 binding to porcine EOS was not 
observed in previous studies of Stx2 binding to porcine granulocytes analyzed by 
fluorescence microscopy (135, 136). This discrepancy may be explained by a difference in 
the methods used to detect Stx2 binding. While both studies used fluorescence microscopy, 
earlier investigations used porcine granulocyte smears that were air-dried prior to incubation 
with Stx2 and detection reagents (135, 136). For similar investigations in the present study, 
viable granulocytes were incubated with Stx2 and detection reagents before being spotted 
onto slides.  
EOS have traditionally been regarded as cells primarily involved in allergies and 
defense against parasitic infections but recent studies show that EOS are involved in antigen 
presentation, localized inflammatory responses and regulation of the adaptive immune 
response (1, 55, 73, 99). Given the broad role of these cells in the immune response and that 
the majority of EOS naturally reside in the gastrointestinal tract (1, 55, 73), any possible 
involvement in Stx-mediated disease should be investigated further.  
Since granulocyte functional assays require incubations at 37°C in cell culture media, 
one objective of this study was to ensure that Stx2 and rStxB2 bind to porcine granulocytes 
under these conditions as they do at 4°C (135). We demonstrated that Stx2 and rStxB2 bound 
to granulocytes at both temperatures and the percentage of positive cells was similar for 
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granulocytes incubated in either flow assay buffer or cell culture medium. We also observed 
a decrease in MFI when granulocytes were incubated with Stx2 or rStxB2 at 37C.  This 
observation led us to hypothesize that Stx2 and rStxB2 are internalized by porcine 
granulocytes.  
Subsequent experiments designed to test the internalization hypothesis showed that 
porcine granulocytes loaded with Stx2 or rStxB2 at 4°C for 30 minutes and transferred to 
37°C for an additional 30 minutes had a lower MFI than granulocytes maintained at 4°C 
throughout. Internalization was presumptively identified by a decrease in Stx2 or rStxB2 
available on the cell surface and accessible to the detection antibodies. To rule out the 
possibility that bound Stx2 or rStxB2 were released from the receptors at 37°C, similar 
experiments were performed where the granulocytes were fixed and permeabilized before 
incubation with the detection antibodies.  Permeabilization allowed the antibodies to access 
internalized as well as surface bound Stx2 or rStxB2.  Although there were still differences in 
the MFI between 4°C and 37°C they were not as pronounced as in the first set of 
experiments.  We interpreted these results as evidence that porcine granulocytes internalized 
a portion of the surface-bound Stx2 and rStxB2. 
Stx2 binds to Gb3/CD77 via the B-subunits while cytotoxicity is mediated via the A-
subunit after internalization and retrograde transport. While many effects of Stx are attributed 
to the enzymatic action of the A-subunit, the B-subunits also have functional effects on some 
cell types. Functional effects of StxB2 are thought to be mediated through signaling 
pathways initiated upon binding to receptors on the cell surface rather than through any direct 
action of the StxB2. Binding of StxB2 to Gb3/CD77 can trigger intracellular signaling events 
(115) and can induce apoptosis in Burkitt’s lymphoma cells (81). Several studies found that 
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the binding of anti-Gb3/CD77 antibodies to these receptors is sufficient to trigger signaling 
pathways and apoptosis (113, 123). We found that porcine granulocytes internalized both 
Stx2 and rStxB2, but only Stx2 had functional effects on the granulocytes. This finding is 
consistent with the interpretation that the observed functional effects resulted from a direct 
action of the holotoxin and not from a signaling cascade initiated upon binding to the 
granulocytes. 
Investigations of the interactions between human PMN and Stx have produced some 
conflicting results. There have been two recent independent reports that Stx binds to PMN in 
vitro (10, 48) and one report that Stx did not bind to PMN in vitro (36). These conflicting 
results can possibly be attributed to differences in the methods used in the various studies. In 
the latter study that failed to detect Stx binding, whole blood was incubated with Stx 
followed by density gradient centrifugation over Ficoll-Paque to obtain the PMN before 
analysis to detect binding (36). Considering the reported low affinity of the Stx receptor on 
human PMN (119) and the sensitivity of PMN to ex vivo handling (137), bound Stx may 
have been removed from the PMN before analysis.  
Most studies of the effects of Stx on apoptosis in human granulocytes have reported 
delayed apoptosis (11, 80) although in one study Stx had no effect on apoptosis (74). Several 
investigations found that incubation of human granulocytes with Stx reduces the ability of 
the cells to respond to subsequent stimulation with PMA resulting in a decrease in the 
oxidative burst response (2, 56, 72). Only one study reported that Stx increased the oxidative 
burst in unstimulated human granulocytes (72), a result that could not be replicated in the 
subsequent investigations (2, 60). There were no major differences in the methods used for 
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the conflicting apoptosis and oxidative burst experiments that could possibly account for 
such discrepancies.  
Granulocytes undergo apoptosis to maintain the number of cells in circulation and to 
control inflammation. It has been proposed that a Stx-mediated delay in apoptosis may 
extend the functional lifespan of granulocytes and increase inflammation and granulocyte-
mediated tissue damage. However, in contrast to our initial hypothesis and to most studies 
with Stx and human granulocytes (10, 77), Stx2 dramatically increased the percentage of 
apoptotic porcine granulocytes. The differences between the effects of Stx on human and 
porcine granulocytes may be explained in part by differences in receptor expression. Porcine 
granulocytes express Gb3/CD77 (136), internalize Stx, and rapidly undergo apoptosis. In 
contrast, human granulocytes express an unknown Stx receptor, have not been shown to 
internalize Stx (119) and Stx delays granulocyte apoptosis. Similar to our findings in pigs, 
Stx also binds to granulocytes of mice and sheep via Gb3/CD77 and accelerates granulocyte 
apoptosis in these species (47, 85). 
The oxidative burst is the primary mechanism by which granulocytes destroy bacteria 
although it can also result in host tissue damage during an inflammatory response. Incubation 
of human granulocytes with Stx in vitro reduces the ability of the cells to respond to 
subsequent stimulation and inhibits the oxidative burst induced by PMA (2, 56, 72). In 
support of our initial hypothesis, incubation with Stx2 reduced the percentage of PMA-
stimulated porcine granulocytes capable of an oxidative burst.  Our findings are consistent 
with those reported for human granulocytes incubated with Stx in vitro and indicate that Stx2 
may also reduce the ability of porcine granulocytes to respond to PMA (2, 56, 72).  
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In experiments aimed at determining the effect of Stx2 on porcine granulocyte 
apoptosis and oxidative burst, LPS was included in order to control for any LPS present in 
the Stx2 and rStxB2 preparations. The finding that LPS and Stx2 have opposite effects on 
both apoptosis and oxidative burst rules out the possibility that any LPS in the preparations 
was responsible for the observed functional effects. LPS has a priming effect on human PMN 
that results in an increased oxidative burst and delayed apoptosis. Our results indicate LPS 
has a similar effect on porcine granulocytes. We did not conduct experiments to determine if 
LPS reduced the functional effects of Stx2 and rStxB2.  
The experiments in this study were conducted with granulocytes isolated from pigs > 
6 months of age. Unlike neonatal and weaned pigs, which are used as models for STEC 
disease (19, 20, 38, 50, 95), older pigs generally do not develop Stx-induced symptoms (7, 
16). Further studies are needed to determine if granulocytes from younger pigs are similarly 
affected by Stx.  
The new information from this study increases our understanding of the interactions 
of Stx and granulocytes in pigs. The studies presented here indicate that Stx2 interacts 
directly with porcine granulocytes. This is, to the best of our knowledge, the first report of 
functional effects of Stx on porcine granulocytes and the first report of Stx binding and 
effects on EOS in any species. The availability of porcine STEC infection models provides 




CHAPTER 6: CONCLUSIONS 
General Summary 
 Stx is considered the primary virulence factor responsible for the development of 
hemorrhagic colitis and HUS in humans. Several lines of evidence indicate that the 
interaction of Stx with granulocytes plays a role in the pathogenesis of Stx-mediated disease 
in humans. Human granulocytes bind Stx and are thought to transport it to target organs 
including the CNS and kidneys. Stx delays granulocyte apoptosis and induces the oxidative 
burst thereby extending the functional lifespan of the cells and may result in increased tissue 
damage. Pigs, animals that are susceptible to natural and experimental infection with STEC 
strains, develop CNS and kidney lesions similar to those observed in humans although the 
mechanism by which Stx reaches these organs is unknown. Stx binds to isolated porcine 
granulocytes in vitro. The studies described here investigated Stx2 binding to isolated 
porcine granulocytes and the functional effects of this binding. The results of these studies 
demonstrate that Stx binds to porcine granulocytes under conditions needed for functional 
studies and alters granulocyte apoptosis and the oxidative burst. 
 
Objective 1 
 We developed a flow cytometric assay to evaluate Stx2 binding at 4°C and under 
conditions suitable for PMN functional studies. The flow cytometric assay developed to 
detect Stx2 binding to porcine granulocytes at 4°C (135) was designed as a rapid assay 
procedure in which primary and secondary detection reagents are combined in the same 
incubation step. Although this type of assay decreases the number of times the cells are 
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handled, combining the detection reagents may result in cross-reactions or reduced staining. 
The rapid assay was compared to a sequential assay procedure with separate incubation and 
wash steps for each reagent. Similar percentages of Stx2 positive granulocytes were detected 
with both assays. There was no change in granulocyte morphology when the sequential 
method was used and staining was not reduced when the rapid assay was used. These results 
indicate that either method may be used to detect Stx2 binding to isolated porcine 
granulocytes without adverse effects. Sequential incubations of primary and secondary 
detection reagents are standard practice for flow cytometry and was the procedure chosen for 
the Stx binding assays. 
An important step before investigating the functional effects of Stx is to ensure that 
Stx binds to porcine granulocytes under the conditions required for function studies as they 
do at 4°C. We hypothesized that Stx binds to porcine granulocytes under conditions required 
for functional studies (37°C in cell culture medium). This set of experiments compared Stx2 
binding to high and low SSC granulocytes at 4°C and 37°C from 15-120 minutes. Stx2 
bound to both high and low SSC granulocytes at 4°C and 37°C. The MFI remained constant 
over time when the granulocytes were incubated with Stx2 at 4°C but decreased over time 
when incubated at 37°C.  
 The observed decrease in MFI when granulocytes were incubated with Stx2 at 37°C 
lead us to hypothesize that Stx2 is internalized by porcine granulocytes. These studies 
compared the MFI of granulocytes incubated with Stx2 at 4°C, washed, then differentially 
incubated at 4°C or 37°C before being incubated at 4°C with detection reagents. 
Internalization of Stx2 presumptively resulted in less surface-bound Stx2 available to the 
detection antibodies and translated into a decreased MFI. Both high SSC and low SSC 
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granulocytes internalized Stx2 and rStxB2. The finding that both Stx2 and rStxB2 are 
internalized will help to determine whether any functional effects are mediated by direct 




 Stx delays apoptosis and decreases the oxidative burst in PMA-stimulated human 
PMN. There are similarities between Stx-mediated disease in humans and pigs and Stx binds 
to both human and porcine granulocytes. This lead to the hypotheses that Stx delays 
apoptosis and impairs the oxidative burst in PMA-stimulated porcine granulocytes as it does 
in human granulocytes. Stx2 increased the percentage of apoptotic granulocytes and 
decreased the percentage of oxidative burst positive granulocytes for both high and low SSC 
populations. Our results did not support the hypothesis that Stx2 delays porcine granulocyte 
apoptosis but did support the second hypothesis that Stx2 impairs the oxidative burst 
response in PMA-stimulated granuloyctes. 
 
Recommendations for Future Research 
 The findings described in this thesis constitute only a small part of the research 
needed to determine the role of granulocytes in Stx-mediated disease in pigs. Numerous 
studies of human HUS patients have reported that Stx can be detected bound to circulating 
granulocytes (9, 117, 120). In this study, Stx2 binding to porcine granulocytes was detected 
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in vitro under several conditions including incubation at 37°C. Stx2 binding to porcine 
granulocytes in vivo could be investigated by utilizing the existing porcine infection models.  
 Studies should be conducted to determine if Stx bound to porcine granulocytes can be 
transferred to other cells expressing Gb3/CD77. In humans, Stx is transferred from 
granulocytes to Stx-sensitive cells that express a high number of Gb3/CD77 in vitro (119). 
Stx bound to granulocytes is transferred to Stx-negative granulocytes in vitro (10). In 
contrast to human granulocytes that express an unknown Stx receptor with low affinity for 
the toxin, porcine granulocytes express Gb3/CD77.   
We reported that Stx2 decreased the percentage of porcine granulocytes capable of an 
oxidative burst when stimulated with PMA. Similar results were obtained with human 
granulocytes when the oxidative burst was induced with PMA (2, 56, 72). However, when 
the oxidative burst was measured without the addition of PMA, Stx induced an oxidative 
burst (72). The effects of Stx2 on the oxidative burst of non-stimulated porcine granulocytes 
should be investigated.  
The studies proposed above would provide further insight into the role of 
granulocytes in Stx-mediated disease in pigs and could provide insight into the mechanism 








Figure 11. Stx2 binding to isolated porcine granulocytes when the Stx2 and granulocytes 
were incubated together on a rotary shaker (white histogram) or statically (shaded 
histogram). Stx2 binding was detected using the sequential detection assay. Stx2 positive 
granulocytes with similar MFI were identified by flow cytometry when either incubation 
method was used. Stx2 bound similarly to high and low SSC granulocytes. Flow cytometry 
histograms are representative of results obtained for each animal (n = 4) from two 
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